Actelion aspires to exploit the potential of endothelin receptor antagonism (ERA) as an approach to new treatments for cardiovascular disease, but the company’s research activities have subsequently expanded through investigating other G-protein coupled receptors and aspartic proteases in additional therapeutic areas. Actelion has two marketed products, Tracleer® (bosentan) for pulmonary arterial hypertension and Zavesca® (miglustat) for type 1 Gaucher's disease.